Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04006392 · ClinicalTrials.gov registry record · NA
An Evaluation of the Effect of Low Level Laser Therapy on Diabetic Peripheral Neuropathy Pain
A NA study, sponsored by Erchonia Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT04006392: Clinical Trial NA study, sponsored by Erchonia Corporation.
NCT04006392 is a NA study that was terminated before completion, run by Erchonia Corporation. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04006392, a NA study, was terminated before completion, sponsored by Erchonia Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether low level laser therapy is effective in the reduction of foot pain associated with diabetic peripheral neuropathy.
Primary Outcome
The Visual Analog Scale (VAS) assesses level or degree of pain. It is a horizontal line anchored on the left by the label '0: no pain at all' and on the right by the label '100: worst pain imaginable'. The subject marks a location on the 0-100 line that appears to represent any level of pain he or she is experiencing at that time. This marking is measured with a 0 to 100 mm ruler and the number recorded. For the primary study outcome, the percent change in the VAS pain score recorded at baseline
Interventions
- DEVICE Placebo Laser
- DEVICE Erchonia FX-635
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-02-15 |
| Est. Completion | 2021-10-05 |
| Phase | NA |
Why NCT04006392 stopped before completion
NCT04006392 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Laser is the first listed.
NCT04006392 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04006392 about?
NCT04006392 is a clinical study titled "An Evaluation of the Effect of Low Level Laser Therapy on Diabetic Peripheral Neuropathy Pain". The purpose of this study is to determine whether low level laser therapy is effective in the reduction of foot pain associated with diabetic peripheral neuropathy.
What is the current status of trial NCT04006392?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2019-02-15. Estimated completion is 2021-10-05.
What interventions are being tested in trial NCT04006392?
The interventions under investigation include: Placebo Laser (DEVICE), Erchonia FX-635 (DEVICE).
Who is sponsoring clinical trial NCT04006392?
This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04006392's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI